

FINAL RESUME ON THE RESEARCH UNIT: Translational Research in Diabetes (TRD)

UNDER THE SUPERVISION OF THE FOLLOWING INSTITUTIONS AND RESEARCH BODIES:

Université de Lille

Centre hospitalier régional et universitaire de
Lille - Chru Lille

Institut national de la santé et de la recherche
médicale - Inserm

Institut Pasteur de Lille

EVALUATION CAMPAIGN 2018-2019 GROUP E

Report published on June, 05 2019



In the name of Hcéres¹:

Michel Cosnard, President

In the name of the experts committee²:

Paul de Vos, Chairman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

¹ The president of Hcéres "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5);

² The evaluation reports "are signed by the chairman of the experts committee". (Article 11, paragraph 2).

Tables in this document were filled with data provided by laboratories and supervising bodies in the unit's application and in the Excel files "Données du contrat en cours" and "Données du prochain contrat".

UNIT PRESENTATION

Unit name:	Translational Research in Diabetes
Unit acronym:	TRD
Requested label:	UMR Inserm
Application type:	Renewal
Current number:	UMR 1190
Head of the unit (2018-2019):	Mr François PATTOU
Project leader (2020-2024):	Mr François PATTOU
Number of teams:	1

EXPERTS COMMITTEE MEMBERS

Chair:	Mr Paul DE VOS, UMCG, The Netherlands
Experts:	Ms Véronique BLOUIN-TAVEL, Inserm Nantes (supporting personnel)
	Mr Stéphane DALLE, Inserm Montpellier (representative of Inserm CSS)
	Mr Etienne LARGER, Université Paris Descartes (representative of CNU)
	Ms Reshma RAMRACHEYA, University of Oxford, United Kingdom

HCÉRES REPRESENTATIVE

Mr Jean-Paul LALLÈS

REPRESENTATIVES OF SUPERVISING INSTITUTIONS AND BODIES

Mr Benoît DEPREZ, Institut Pasteur de Lille

Mr Frédéric GOTTRAND, Chru de Lille

Mr Lionel MONTAGNE, Université de Lille

Mr Samir OUL-ALI, Inserm

INTRODUCTION

HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The research unit "Translational Research in diabetes" is a unit of the Université Lille-Inserm. After being a University team (EA 1044), the unit was labelled by Inserm as ERIT-M in 2000, before becoming UNIT-M in 2005 and UMR 859. It is also one of the three components of the Research Federation "European Genomic Institute for Diabetes" (EGID). In 2009, the unit combined efforts with the units UMR 8199 (Head: P. FROGUEL) and UMR 1011 (Head: Mr B. STAELS) to form the EGID Research Federation which was awarded in 2011 as Laboratory of Excellence (Labex) by the "Programme d'Investissements d'Avenir" (PIA).

The unit is located on the Lille University Hospital campus, in the Pole Recherche of the Faculty of Medicine. It includes the Biotherapy Platform for human islet production, in immediate vicinity with the new EGID building where the EGID's administration, the animal facility (rodents and minipigs) and the EGID-Biotech platform (industry-academic platform) are located, and with Huriez Hospital where clinical studies are conducted.

MANAGEMENT TEAM

The director of the unit is Mr François Pattou, the deputy director is Ms Julie Kerr-Conte.

HCÉRES NOMENCLATURE

SVE5

SCIENTIFIC DOMAIN

The unit focuses on diabetes translational research and in particular to human islet transplantation and metabolic surgery. The goal of the research unit is to develop innovative therapies for severe forms of diabetes and clinical application thereof. There are two major research lines within this topic: (i) human islet transplantation for treatment of type 1 diabetes and (ii) the treatment of type 2 diabetes by metabolic surgery.

UNIT WORKFORCE

	Unit workforce	
	Translational Research for Diabetes (TRD)	
Active staff	Number 30/06/2018	Number 01/01/2020
Full professors and similar positions	5	5
Assistant professors and similar positions	1	1
Full time research directors (Directeurs de recherche) and similar positions	0	0
Full time research associates (Chargés de recherche) and similar positions	1	4
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	0	0
High school teachers	0	0

Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	22	18
Permanent staff	29	28
Non-permanent professors and associate professors, including emeritus	0	
Non-permanent full time scientists, including emeritus, post-docs	0	
<i>PhD Students</i>	3	
Non-permanent supporting personnel	1	
Non-permanent staff	4	
Total	33	

GLOBAL ASSESSMENT OF THE UNIT

The unit is performing very well. It has two major line of research, i.e. islet transplantation to cure type I diabetes and metabolic surgery as therapy for type II diabetes. The team has a very strong publication record and keeps on publishing in high ranking journals. Its international reputation is excellent and the unit collaborates with many centers in France by delivering of high-quality islets. The unit has an excellent organisation and life for both young and more senior researchers. The unit has a clear vision and focus on two research lines but the committee considers the limited time the staff can spend on the large number of subprojects a threat.

The evaluation reports of Hceres
are available online : www.hceres.com

Evaluation of clusters of higher education and research institutions

Evaluation of higher education and research institutions

Evaluation of research

Evaluation of doctoral schools

Evaluation of programmes

International evaluation and accreditation



2 rue Albert Einstein
75013 Paris, France
T. 33 (0)1 55 55 60 10

hceres.com

[@Hceres_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)